2. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M. et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–23. https://doi.org/10.1093/ageing/afq034. PMID: 20392703. PMCID: PMC2886201.

3. Anker S.D., Morley J.E., von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016; 7(5): 512–14. https://doi.org/10.1002/jcsm.12147. PMID: 27891296. PMCID: PMC5114626.

4. Cruz-Jentoft A.J., Bahat G., Bauer J. et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1): 16–31. https://doi.org/10.1093/ageing/afy169. PMID: 30312372. PMCID: PMC6322506.

5. Ishibashi H. Locomotive syndrome in Japan. Osteoporos Sarcopenia. 2018; 4(3): 86–94. https://doi.org/10.1016/j.afos.2018.09.004. PMID: 30775549. PMCID: PMC6362958.

6. Сафонова Ю.А., Торопцова Н.В. Частота и факторы риска саркопении у людей старших возрастных групп. Клиницист. 2022; 16(2): 40–47. (Safonova Yu.A., Toroptsova N.V. Frequency and risk factors of sarcopenia in the elderly people. Klinitsist = The Clinician. 2022; 16(2): 40–47 (In Russ.)). https://doi.org/10.17650/1818-8338-2022-16-2-K661. EDN: NANRHO.

7. Калейчик М.С., Большакова Т.Ю., Капустина Е.В. с соавт. Распространенность саркопении у пациентов кардиологического стационара. Врач. 2020; 31(9): 71–75. (Kaleichik M.S., Bolshakova T.Yu., Kapustina E.V. et al. The prevalence of sarcopenia in cardiology hospital patients. Vrach = The Doctor. 2020; 31(9): 71–75 (In Russ.)). https://doi.org/10.29296/25877305-2020-09-13. EDN: ZTEXXA.

8. Баздырев Е.Д., Терентьева Н.А., Кривошапова К.Е. с соавт. Распространенность нарушений опорно-двигательного аппарата у больных ишемической болезнью сердца. Рациональная фармакотерапия в кардиологии. 2021; 17(3): 369–375. (Bazdyrev E.D., Terentieva N.A., Krivoshapova K.E. et al. The prevalence of disorders of the musculoskeletal system in patients with coronary heart disease. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2021; 17(3): 369–375 (In Russ.)). https://doi.org/10.20996/1819-6446-2021-06-03. EDN: RIBHPR.

9. Abe T., Iwata K., Yoshimura Y. et al. Low muscle mass is associated with walking function in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2020; 29(11): 105259. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105259. PMID: 33066891.

10. Jones S.E., Maddocks M., Kon S.S. et al. Sarcopenia in COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015; 70(3): 213–18. https://doi.org/10.1136/thoraxjnl-2014-206440. PMID: 25561517.

11. Сулейманова А.К., Сафонова Ю.А., Баранова И.А. Частота саркопении у пациентов со стабильной хронической обструктивной болезнью легких: сравнение диагностических алгоритмов Европейской рабочей группы по саркопении у пожилых людей (редакции 2010 и 2018 гг.). Пульмонология. 2019; 29(5): 564–570. (Suleymanova A.K., Safonova Yu.A., Baranova I.A. An incidence of sarcopenia in patients with stable chronic obstructive pulmonary disease: a comparison of diagnostic algorithms of European Working Group on Sarcopenia in Older People, 2018 versus 2010. Pulmonologiya = Pulmonology. 2019; 29(5): 564–570 (In Russ.)). https://doi.org/10.18093/0869-0189-2019-29-5-564-570. EDN: ZODKSZ.

12. Ai Y., Xu R., Liu L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetol Metab Syndr. 2021; 13(1): 93. https://doi.org/10.1186/s13098-021-00707-7. PMID: 34479652. PMCID: PMC8414692.

13. Shu X., Lin T., Wang H. et al. Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022; 13(1): 145–58. https://doi.org/10.1002/jcsm.12890. PMID: 34989172. PMCID: PMC8818609.

14. Лаврищева Ю.В., Яковенко А.А., Румянцев А.Ш., Кулаева Н.Н. Эпидемиология пресаркопении/саркопении у пациентов на хроническом гемодиализе. Нефрология и диализ. 2019; 21(3): 320–325. (Lavrishcheva Yu.V., Yаkovenko A.A., Rumyancev A.Sh., Kulaeva N.N. Epidemiology of presarcopenia/sarcopenic dermatitis in patients undergoing chronic hemodialysis. Nefrologiya i dializ = Nephrology and Dialysis. 2019; 21(3): 320–325 (In Russ.)). https://doi.org/10.28996/2618-9801-2019-3-320-325. EDN: ALKGFB

15. Zhang J.Z., Shi W., Zou M. et al. Diagnosis, prevalence, and outcomes of sarcopenia in kidney transplantation recipients: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023; 14(1): 17–29. https://doi.org/10.1002/jcsm.13130. PMID: 36403578. PMCID: PMC9891953.

16. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Левченко А.И. Распространенность саркопении у пациентов с хроническим панкреатитом: метаанализ. Терапевтический архив. 2020; 92(12): 43–47. (Maev I.V., Andreev D.N., Kucheryavyy Yu.A., Levchenko A.I. The prevalence of sarcopenia in patients with chronic pancreatitis: A meta-analysis. Terapevticheskiy arkhiv = Therapeutic Archive. 2020; 92(12): 43–47 (In Russ.)). https://doi.org/10.26442/00403660.2020.12.200430. EDN: BYOUHM.

17. Салимов У.Р., Стома И.О., Федорук Д.А. с соавт. Саркопения хронических болезней печени. Можем ли мы предвидеть осложнения? Трансплантология. 2022; 14(4): 408–420. (Salimov U.R., Stoma I.O., Fedoruk D.A. et al. Sarcopenia in chronic liver disease, can we predict complications? Transplantologiya = The Russian Journal of Transplantation. 2022; 14(4): 408–420 (In Russ.)). https://doi.org/10.23873/2074-0506-2022-14-4-408-420. EDN: SSIPOO.

18. Сорокина А.О., Демин Н.В., Добровольская О.В. с соавт. Патологические фенотипы состава тела у больных ревматическими заболеваниями. Научно-практическая ревматология. 2022; 60(4): 487–494. (Sorokina A.O., Demin N.V., Dobrovolskaya O.V. et al. Pathological phenotypes of body composition in patients with rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2022; 60(4): 487–494 (In Russ.)). https://doi.org/10.47360/1995-4484-2022-487-494. EDN: SYZXRF.

19. Сафонова Ю.А., Зоткин Е.Г. Саркопения у пациенток старшего возраста с остеоартритом крупных суставов. Научно-практическая ревматология. 2019; 57(2): 154–159. (Safonova Yu.A., Zotkin E.G. Sarcopenia in older patients with osteoarthritis of large joints. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2019; 57(2): 154–159 (In Russ.)). https://doi.org/10.14412/1995-4484-2019-154-159. EDN: CHGYZL.

20. Shafiee G., Keshtkar A., Soltani A. et al. Prevalence of sarcopenia in the world: A systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017; 16: 21. https://doi.org/10.1186/s40200-017-0302-x. PMID: 28523252. PMCID: PMC5434551.

21. Tan L.-J., Liu S.-L., Lei S.-F. et al. Molecular genetic studies of gene identification for sarcopenia. Hum. Genet. 2011; 131(1): 1–31. https://doi.org/10.1007/s00439-011-1040-7. PMID: 21706341.

22. Bodine S.C., Stitt T.N., Gonzalez M. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001; 3(11): 1014–19. https://doi.org/10.1038/ncb1101-1014. PMID: 11715023.

23. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda). 2008; 23: 160–70. https://doi.org/10.1152/physiol.00041.2007. PMID: 18556469.

24. Busquets S., Deans C., Figueras M. et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr. 2007; 26(5): 614–18. https://doi.org/10.1016/j.clnu.2007.06.005. PMID: 17688974.

25. Penna F., Costamagna D., Pin F. et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol. 2013; 182(4): 1367–78. https://doi.org/10.1016/j.ajpath.2012.12.023. PMID: 23395093.

26. Kang C., Chung E., Diffee G., Ji L.L. Exercise training attenuates aging-associated mitochondrial dysfunction in rat skeletal muscle: Role of PGC-1α. Exp Gerontol. 2013; 48(11): 1343–50. https://doi.org/10.1016/j.exger.2013.08.004. PMID: 23994518.

27. Verdijk L.B., Koopman R., Schaart G. et al. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab. 2007; 292(1): E151–57. https://doi.org/10.1152/ajpendo.00278.2006. PMID: 16926381.

28. Muscaritoli M., Anker S.D., Argiles J. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) «cachexia-anorexia in chronic wasting diseases» and «nutrition in geriatrics». Clin Nutr. 2010; 29(2): 154–59. https://doi.org/10.1016/j.clnu.2009.12.004. PMID: 20060626ю

29. Drummond M.J., Miyazaki M., Dreyer H.C. et al. Expression of growth-related genes in young and older human skeletal muscle following an acute stimulation of protein synthesis. J Appl Physiol (1985). 2009; 106(4): 1403–11. https://doi.org/10.1152/japplphysiol.90842.2008. PMID: 18787087. PMCID: PMC2698637.

30. Bhasin S., Taylor W.E., Singh R. et al. The mechanisms of androgen effects on body composition: Mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci. 2003; 58(12): M1103–10. https://doi.org/10.1093/gerona/58.12.m1103. PMID: 14684707.

31. Cohen H.J., Pieper C.F., Harris T. et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997; 52(4): M201–8. https://doi.org/10.1093/gerona/52a.4.m201. PMID: 9224431.

32. Fielding R.A., Vellas B., Evans W.J. et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011; 12(4): 249–56. https://doi.org/10.1016/j.jamda.2011.01.003. PMID: 21527165. PMCID: PMC3377163.

33. Brown W.F. A method for estimating the number of motor units in thenar muscles and the changes in motor unit count with ageing. J Neurol Neurosurg Psychiatry. 1972; 35(6): 845–52. https://doi.org/10.1136/jnnp.35.6.845. PMID: 4647858. PMCID: PMC494191.

34. Malmstrom T.K., Miller D.K., Simonsick E.M. et al. SARC-F: A symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1): 28–36. https://doi.org/10.1002/jcsm.12048. PMID: 27066316. PMCID: PMC4799853.

35. Торопцова Н.В., Добровольская О.В., Ефремова А.О., Никитинская О.А. Диагностическая значимость опросника SARC-F и тестов оценки мышечной силы для выявления саркопении у больных ревматоидным артритом. Научно-практическая ревматология. 2020; 58(6): 678–682. (Toroptsova N.V., Dobrovolskaya O.V., Efremova A.O., Nikitinskaya O.A. Diagnostic value of the SARC-f questionnaire and muscle strength tests for the detection of sarcopenia in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2020; 58(6): 678–682 (In Russ.)). https://doi.org/10.47360/1995-4484-2020-678-682. EDN: QGKYYP.

36. Lemos T., Gallagher D. Current body composition measurement techniques. Curr Opin Endocrinol Diabetes Obes. 2017; 24(5): 310–14. https://doi.org/10.1097/MED.0000000000000360. PMID: 28696961. PMCID: PMC5771660.

37. Kendler D.L., Borges J.L., Fielding R.A. et al. The official positions of the International Society for Clinical Densitometry: Indications of use and reporting of DXA for Body composition. J Clin Densitom. 2013; 16(4): 496–507. https://doi.org/10.1016/j.jocd.2013.08.020. PMID: 24090645.

38. Yu R., Leung J., Woo J. Incremental predictive value of sarcopenia for incident fracture in an elderly Chinese cohort: Results from the Osteoporotic Fractures in Men (MrOs) Study. J Am Med Dir Assoc. 2014; 15(8): 551–58. https://doi.org/10.1016/j.jamda.2014.02.005. PMID: 24703927.

39. Yoo J.I., Kim H., Ha Y.C. et al. Osteosarcopenia in patients with hip fracture is related with high mortality. J Korean Med Sci. 2018; 33(4): e27. https://doi.org/10.3346/jkms.2018.33.e27. PMID: 29318794. PMCID: PMC5760812.

40. Всероссийская научно-практическая конференция с международным участием «Дни остеопороза в Санкт-Петербурге», 16–17 марта 2023 г., Санкт-Петербург. Сборник тезисов. Остеопороз и остеопатии. 2023; 26(1S): S3–S61. (All-Russian scientific and practical conference with international participation “Days of osteoporosis in Saint Petersburg”, March 16–17, 2023, Saint Petersburg. Collection of abstracts. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2023; 26(1S): S3–S61 (In Russ.)). https://doi.org/10.14341/osteo2023261S.

41. Yoshimura Y., Wakabayashi H., Yamada M. et al. Interventions for treating sarcopenia: A systematic review and meta-analysis of randomized controlled studies. J Am Med Dir Assoc. 2017; 18(6): 553.e1–553.e16. https://doi.org/10.1016/j.jamda.2017.03.019. PMID: 28549707.

42. Beaudart C., Buckinx F., Rabenda V. et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014; 99(11): 4336–45. https://doi.org/10.1210/jc.2014-1742. PMID: 25033068.

43. de Mello R.G.B., Dalla Corte R.R., Gioscia J., Moriguchi E.H. Effects of physical exercise programs on sarcopenia management, dynapenia, and physical performance in the elderly: A systematic review of randomized clinical trials. J Aging Res. 2019; 2019: 1959486. https://doi.org/10.1155/2019/1959486. PMID: 31827927. PMCID: PMC6886343.

44. Rizzoli R., Stevenson J.C., Bauer J.M. et al. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas. 2014; 79(1): 122–32. https://doi.org/10.1016/j.maturitas.2014.07.005. PMID: 25082206.

45. Holm L., Olesen J.L., Matsumoto K. et al. Protein-containing nutrient supplementation following strength training enhances the effect on muscle mass, strength, and bone formation in postmenopausal women. J Appl Physiol (1985). 2008; 105(1): 274–81. https://doi.org/10.1152/japplphysiol.00935.2007. PMID: 18467544.

46. Houston D.K., Nicklas B.J., Ding J. et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: The Health, Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr. 2008; 87(1): 150–55. https://doi.org/10.1093/ajcn/87.1.150. PMID: 18175749.

47. Bauer J., Biolo G., Cederholm T. et al. Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013; 14(8): 542e59. https://doi.org/10.1016/j.jamda.2013.05.021. PMID: 23867520.

48. Hickson M. Nutritional interventions in sarcopenia: A critical review. Proceedings of the Nutrition Society. 2015; 74(4): 378–86. https://doi.org/10.1017/S0029665115002049.

49. Cruz-Jentoft A.J., Landi F., Schneider S.M. et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014; 43(6): 748–59. https://doi.org/10.1093/ageing/afu115. PMID: 25241753. PMCID: PMC4204661.

50. Bear D.E., Cruz-Jentoft A.J., Stout J.R. β-hydroxy-β-methylbutyrate supplementation in older persons – an update. Curr Opin Clin Nutr Metab Care. 2021; 24(1): 48–52. https://doi.org/10.1097/MCO.0000000000000713. PMID: 33148945.

51. Candow D.G., Chilibeck P.D., Forbes S.C. et al. Creatine supplementation for older adults: Focus on sarcopenia, osteoporosis, frailty and Cachexia. Bone. 2022; 162: 116467. https://doi.org/10.1016/j.bone.2022.116467. PMID: 35688360.

52. Beaudart C., Dawson A., Shaw C. Nutrition and physical activity in the prevention and treatment of sarcopenia: Systematic review. Osteoporos Int. 2017; 28(6): 1817–33. https://doi.org/10.1007/s00198-017-3980-9. PMID: 28251287. PMCID: PMC5457808.

53. Лесняк О.А., Баранова И.А., Белая Ж.Е. Остеопороз. Руководство для врачей. 2-е издание, переработанное и дополненное. Под ред. О.А. Лесняк. М.: ГЭОТАР-Медиа. 2023; 752 с. (Lesnyak O.A., Baranova I.A., Belaya Zh.E. Osteoporosis. Guide for physicians. 2nd edition, revised and expanded. Ed. by Lesnyak O.A. Moscow: GEOTAR-Media. 2023; 752 pp. (In Russ.)). ISBN: 978-5-9704-7145-6.

54. Antoniak A.E., Greig C.A. The effect of combined resistance exercise training and vitamin D3 supplementation on musculoskeletal health and function in older adults: A systematic review and meta-analysis. BMJ Open. 2017; 7(7): e014619. https://doi.org/10.1136/bmjopen-2016-014619. PMID: 28729308. PMCID: PMC5541589.

55. Bunout D., Barrera G., Leiva L. et al. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol. 2006; 41(8): 746–52. https://doi.org/10.1016/j.exger.2006.05.001. PMID: 16797903.

56. Binder E.F. Implementing a structured exercise program for frail nursing home residents with dementia: Issues and challenge. JAPA. 1996; 3(4): 383–95. https://doi.org/10.1123/japa.3.4.383.

57. Verhaar H.J., Samson M.M., Jansen P.A. et al. Muscle strength, functional mobility and vitamin D in older women. Aging (Milano). 2000; 12(6): 455–60. https://doi.org/10.1007/BF03339877. PMID: 11211956.

58. Scharla S.H., Schacht E., Bawey S. et al. Pleiotropic effects of alfacalcidol in elderly patients with rheumatoid arthritis. Arthr Rheum. 2003; 23: 268–74.

59. Dukas L., Bischoff H.A., Lindpaintner L.S. et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004; 52(2): 230–36. https://doi.org/10.1111/j.1532-5415.2004.52060.x. PMID: 14728632.

60. Dukas L., Schacht E., Mazor Z., Stahelin H.B. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of < 65 ml/min. Osteoporos Int. 2005; 16(2): 198–203. https://doi.org/10.1007/s00198-004-1671-9. PMID: 15221207.

61. Hirschfeld H.P., Kinsella R., Duque G. Osteosarcopenia: Where bone, muscle, and fat collide. Osteoporos Int. 2017; 28(10): 2781–90. https://doi.org/10.1007/s00198-017-4151-8. PMID: 28733716.

62. Cho M.R., Lee S., Song S.K. A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. J Korean Med Sci. 2022; 37(18): e146. https://doi.org/10.3346/jkms.2022.37.e146. PMID: 35535373. PMCID: PMC9091430.